A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
Public ClinicalTrials.gov record NCT02431468. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease. The study is 15 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose of study drug.
Study identification
- NCT ID
- NCT02431468
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 147 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2015
- Primary completion
- Jan 31, 2017
- Completion
- Jan 31, 2017
- Last update posted
- Jul 5, 2018
2015 – 2017
United States locations
- U.S. sites
- 29
- U.S. states
- 16
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Xenoscience, Inc/ 21st Century Neurology | Phoenix | Arizona | 85004 | — |
| ATP Clinical Research, Inc. | Costa Mesa | California | 92626 | — |
| Nader Pharmacology Research Institute | Los Alamitos | California | 90720 | — |
| San Francisco Clinical Research Center | San Francisco | California | 94109 | — |
| JEM Research | Atlantis | Florida | 33462 | — |
| Brain Matters Research | Delray Beach | Florida | 33445 | — |
| Neuropsychiatric Research Center of South Florida | Fort Myers | Florida | 33912 | — |
| Alzheimer's Research and Treatment Center | Lake Worth | Florida | 33449 | — |
| Miami Jewish Health System | Miami | Florida | 33137 | — |
| Medical Research Group of Central Florida | Orange City | Florida | 32763 | — |
| Compass Research, LLC | Orlando | Florida | 32806 | — |
| Axiom Clinical Research of Florida | Tampa | Florida | 33609 | — |
| Compass Research | The Villages | Florida | 32162 | — |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30331 | — |
| iResearch Atlanta | Decatur | Georgia | 30030 | — |
| Alexian Brothers Neurosciences Institute Clinical Research | Elk Grove Village | Illinois | 60007 | — |
| University of Kansas Alzheimer's Disease Center | Fairway | Kansas | 66205 | — |
| Lake Charles Clinical Trials | Lake Charles | Louisiana | 70629 | — |
| J. Gary Booker, MD APMC Clinical Drug Trials | Shreveport | Louisiana | 71104 | — |
| Millennium Psychiatric Associates | Creve Coeur | Missouri | 63141 | — |
| Atlantic Neuroscience Institute | Springfield | New Jersey | 07801 | — |
| Neurological Associates of Albany, PC | Albany | New York | 12208 | — |
| Parker Jewish Institute for Health Care and Rehabilitation | New Hyde Park | New York | 11040 | — |
| Alzheimer's Memory Center | Charlotte | North Carolina | 28270 | — |
| Neurobehavioral Clinical Research | Canton | Ohio | 44718 | — |
| Oklahoma Clinical Research Center | Oklahoma City | Oklahoma | 73112 | — |
| Sunstone Clinical Research | Medford | Oregon | 97504 | — |
| The Clinical Trial Center, LLC | Jenkintown | Pennsylvania | — | — |
| Neurology Clinic, PC | Cordova | Tennessee | 38018 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Alzheimer's Disease trials
Other public records listing Alzheimer's Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT07780383: A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration Not yet recruiting
- NCT07775625: Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music Recruiting
- NCT06976203: A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) Recruiting
- NCT07688213: A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease Recruiting
- NCT07721467: Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Not yet recruiting
- NCT00869817: Dominantly Inherited Alzheimer Network (DIAN) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02431468, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 5, 2018 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02431468 live on ClinicalTrials.gov.